Patient Group Direction (PGD) Template

Administration of

AstraZeneca COVID-19 Vaccine (ChAdOx1-S [Recombinant])

Note other COVID19 vaccines are not covered by this PGD – separate PGDs will be available.

Publication date: 31 December 2020

This specimen patient group direction (PGD) template has been produced by Public Health Scotlandto assist NHS boards.

NHS boards should amend/adapt this PGD template and must ensure that the PGD is considered and approved in line with local clinical governance arrangements for PGDs.

Version history

|  |  |  |
| --- | --- | --- |
| Version | Date | Summary of changes |
| 1.0 | 31/12/20 | New PGD |
|  |  |  |

Contents

[Authorisation 4](#_Toc60297524)

[Clinical situation 5](#_Toc60297525)

[Description of treatment 8](#_Toc60297526)

[Adverse reactions 12](#_Toc60297527)

[Characteristics of staff authorised under the PGD 15](#_Toc60297528)

[Audit trail 17](#_Toc60297529)

[Additional references 18](#_Toc60297530)

[PGD for administration of COVID-19 Vaccine (ChAdOx1-S [recombinant]) AstraZeneca PGD v1.0 Valid from: 31/12/2020 Expiry: 30/11/2021 - authorisation 19](#_Toc60297531)

# Authorisation

## PGD COVID-19 AstraZeneca COVID-19 Vaccine (ChAdOx1-S [Recombinant])

This specimen Patient Group Direction (PGD) template has been produced by Public Health Scotland to assist NHS boards. NHS boards should ensure that the final PGD is considered and approved in line with local clinical governance arrangements for PGDs.

The qualified health professionals who may administer AstraZeneca COVID-19 Vaccine (ChAdOx1-S [Recombinant]) under this PGD can only do so as named individuals. It is the responsibility of each professional to practice within the bounds of their own competence and in accordance with their own Code of Professional Conduct and to ensure familiarity with the manufacturer’s product information/summary of product characteristics (SPC) for all vaccines administered in accordance with this PGD.

NHS board governance arrangements will indicate how records of staff authorised to operate this PGD will be maintained. Under PGD legislation there can be no delegation. Administration of the vaccine has to be by the same practitioner who has assessed the patient under the PGD.

**This PGD has been produced for NHS** ……………………………………………… **by:**

**Doctor** .……………………………………………….... **Signature**

**Pharmacist** .…………………………………………… **Signature**

**Nurse** …………………………………………………… **Signature**

**Approved on behalf of NHS** …………………………………………………… **by:**

**Medical Director** ……………………………………… **Signature**

**Director of Pharmacy/  
Senior Pharmacist** …………………………………… **Signature**

**Clinical Governance Lead** …………………………. **Signature**

**Date approved:**

**Effective from:** 31/12/2020 **Review date:** 30/11/2021

# Clinical situation

|  |  |
| --- | --- |
| Category | Description |
| **Indication** | AstraZeneca COVID-19 Vaccine (ChAdOx1-S [Recombinant]) is indicated for active immunisation against COVID-19 disease caused by SARS-CoV-2 virus in accordance with Scottish Government COVID-19 immunisation programme and recommendations given in Chapter 14a of the Immunisation Against Infectious Disease: the ‘Green Book’, JCVI statement on priority groups for COVID-19 vaccination from 30th December 2020 and subsequent correspondence/publications from Scottish Government. |
| **Inclusion criteria** | National policy must be followed in relation to the priority groups eligible for vaccination at a particular point in time.  COVID-19 vaccine should be offered to the following individuals:   * Residents in a care home for older adults and their carers * All those 80 years of age and over * Frontline health and social care workers (as included in COVID-19 –SARS-Cov-2 chapter of Green Book, JCVI statement and Scottish Government CMO letters) * All those 75 years of age and over * All those 70 years of age and over * Clinically extremely vulnerable (CEV) individuals (not including all pregnant women and those under 18 years) as defined by Scottish Government at <https://www.gov.scot/publications/covid-shielding/pages/highest-risk-classification/> * All those 65 years of age and over * Individuals aged 18 years to 64 years with underlying health conditions which puts them at higher risk of serious disease and mortality included in Table 3 COVID-19 –SARS-Cov-2 chapter 14a of Green Book\* * All those 60 years of age and over * All those 55 years of age and over * All those 50 years of age and over * Further guidance for those under age 50 years not included in the above groups will follow in phase 2.   \*This also includes those who are in receipt of a carer’s allowance, or those who are the main carer of an elderly or disabled person whose welfare may be at risk if the carer falls ill.  The list above is not exhaustive, and clinician should apply clinical judgment to take into account the risk of COVID-19 exacerbating any underlying disease that a patient may have, as well as the risk of serious illness from COVID-19 itself. COVID-19 vaccine should be offered in such cases even if the individual is not in the clinical risk groups specified above, this may be provided under a Patient Specific Direction (PSD). |
| **Exclusion criteria** | The vaccine should not be given to:   * Those who have had a confirmed anaphylactic reaction to a previous dose of this COVID-19 vaccine * Those who have had a confirmed anaphylactic reaction to any components of this vaccine * Those in whom no valid consent has been received * Those who are under 18 years of age * Women who are known to be pregnant (routine questioning about last menstrual period and/or pregnancy testing is not required before offering the vaccine) * Those with confirmed COVID-19 infection to avoid confusing the differential diagnosis. As clinical deterioration can occur up to two weeks after infection, ideally vaccination should be deferred until around four weeks after onset of symptoms or from the first PCR positive specimen in those who are asymptomatic. * Those with evidence of current deterioration of COVID-19 symptoms, deferral of vaccination may be considered to avoid incorrect attribution of any change in the person’s underlying condition to the vaccine. * Those who are participating in a clinical trial of COVID-19 vaccines * Those with acute febrile illness – consider postponing immunisation until individual has fully recovered. * Those with evolving neurological condition – consider postponing immunisation until individual has stabilised. |
| **Cautions/need for further advice/ circumstances when further advice should be sought from a doctor** | The COVID-19 chapter of the Green Book advises that there are very few individuals who cannot receive COVID vaccine. Where there is doubt, rather than withholding vaccination, appropriate advice should be sought from the relevant specialist, or from the local immunisation or health protection team.  The MHRA has advised that individuals with a history of anaphylaxis to food, an identified drug or vaccine, or an insect sting can receive any COVID-19 vaccine, as long as they are not known to be allergic to any component of the vaccine.  Individuals with a bleeding disorder may develop a haematoma at the injection site (see Route of Administration).  Because of the absence of data on co-administration with COVID-19 vaccines, it should not be routine to offer appointments to give this vaccine at the same time as other vaccines. Based on current information about the first COVID-19 vaccines being deployed, scheduling should ideally be separated by an interval of at least 7 days to avoid incorrect attribution of potential adverse events.  As AstraZeneca COVID-19 Vaccine (ChAdOx1-S [Recombinant]) is considered inactivated, where individuals in an eligible cohort present having received another inactivated or live vaccine, COVID-19 vaccination should still be considered. The same applies for other live and inactivated vaccines where COVID-19 vaccination has been received first. In many cases, vaccination should proceed to avoid any further delay in protection and to avoid the risk of the patient not returning for a later appointment. In such circumstances, patients should be informed about the likely timing of potential adverse events relating to each vaccine.  Syncope (fainting) can occur following, or even before, any vaccination especially in adolescents as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from faints.  JCVI advise there is no known risk associated with giving these types of vaccines during pregnancy. These vaccines cannot replicate, so they cannot cause infection in either the woman or the unborn child.  Although the available data do not indicate any safety concern or harm to pregnancy, there is insufficient evidence to recommend routine use of COVID-19 vaccines during pregnancy.  JCVI advises that, for women who are offered vaccination with the Pfizer-BioNTech or AstraZeneca COVID-19 vaccines, vaccination in pregnancy should be considered where the risk of exposure to Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV2) infection is high and cannot be avoided, or where the woman has underlying conditions that put them at very high risk of serious complications of COVID-19. In these circumstances, clinicians should discuss the risks and benefits of vaccination with the woman, who should be told about the absence of safety data for the vaccine in pregnant women.  There is no known risk associated with giving non-live vaccines whilst breastfeeding. JCVI advises that breastfeeding women may be offered vaccination with the Pfizer-BioNTech or AstraZeneca COVID-19 vaccines.  The developmental and health benefits of breastfeeding should be considered along with the woman’s clinical need for immunisation against COVID-19, and the woman should be informed about the absence of safety data for the vaccine in breastfeeding women. |
| **Action if excluded** | Specialist advice should be sought on the vaccine and circumstances under which it could be given as vaccination using a patient specific direction may be indicated.  Individuals who are participating in a clinical trial of COVID-19 vaccines who present for vaccination should be referred back to the investigators.  In case of postponement due to acute illness or evolving neurological condition, advise when the individual can be vaccinated and ensure another appointment is arranged.  In case of postponement due to COVID-19 symptoms or positive COVID test in the last four weeks advise when the individual can be vaccinated and how future vaccination may be accessed.  Document the reason for exclusion and any action taken in accordance with local procedures. |
| **Action if patient declines** | Advise the individual/carer about the protective effects of the vaccine, the risks of infection and potential complications if not immunised.  Advise how future immunisation may be accessed if they subsequently decide to receive the COVID-19 vaccine  Document patient’s declined consent and advice given. |

# Description of treatment

|  |  |
| --- | --- |
| Category | Description |
| **Name of medicine** | AstraZeneca COVID-19 Vaccine (ChAdOx1-S [Recombinant]), solution for injection in a multidose container  AstraZeneca COVID-19 Vaccine (ChAdOx1-S [Recombinant]) |
| **Form/strength** | AstraZeneca COVID-19 Vaccine (ChAdOx1-S [Recombinant]) solution for injection multidose vials containing:  5ml of solution in a 10-dose vial; or  4ml of solution in an 8-dose vial |
| **Route of** **administration** | AstraZeneca COVID-19 Vaccine (ChAdOx1-S [Recombinant]) must be administered by intramuscular (IM) injection preferably into the deltoid area of the upper arm. Where administration into the deltoid is not possible the anterolateral thigh can be considered.  Inspect visually prior to administration and ensure appearance is consistent with the description in the manufacturer’s product literature or summary of product characteristics.  Individuals with bleeding disorders may be vaccinated intramuscularly if, in the opinion of a doctor familiar with individual’s bleeding risk, vaccines or similar small volume intramuscular injections can be administered with reasonable safety by this route. If the individual receives medication/ treatment to reduce bleeding, for example treatment for haemophilia, intramuscular vaccination can be scheduled shortly after such medication/treatment is administered. Individuals on stable anticoagulation therapy, including individuals on warfarin who are up-to-date with their scheduled INR testing and whose latest INR is below the upper level of the therapeutic range, can receive intramuscular vaccination. A fine needle (23 or 25 gauge) should be used for the vaccination, followed by firm pressure applied to the site without rubbing for at least 2 minutes. The individual/parent/carer should be informed about the risk of haematoma from the injection.  The site at which each vaccine was given should be noted in the individual’s records. |
| **Dosage** | The dose of AstraZeneca COVID-19 Vaccine (ChAdOx1-S [Recombinant]) is 0.5mL |
| **Frequency** | AstraZeneca COVID-19 Vaccine (ChAdOx1-S [Recombinant]) course consists of two separate doses of 0.5ml each, a minimum of 28 days apart.  Operationally, it is recommended in the COVID-19 chapter of Green Book that the second dose of both vaccines should be routinely scheduled between four and 12 weeks after the first dose. This will allow more people to benefit from the protection provided from the first dose during the roll out phase. Longer term protection will then be provided by the second dose.  If an interval longer than the recommended interval is left between doses, the second dose should still be given (preferably using the same vaccine as was given for the first dose if possible). The course does not need to be restarted.  JCVI advises that the second vaccine dose should be with the same vaccine as for the first dose. Switching between vaccines or missing the second dose is not advised as this may affect the duration of protection.  There is no evidence on the interchangeability of the COVID-19 vaccines although studies are underway. Therefore, every effort should be made to determine which vaccine the individual received and to complete with the same vaccine. For individuals who started the schedule and who attend for vaccination at a site where the same vaccine is not available, or if the first product received is unknown, it is reasonable to offer a single dose of the locally available product. This option is preferred if the individual is likely to be at immediate high risk or is considered unlikely to attend again. In these circumstances, as both the vaccines are based on the spike protein, it is likely the second dose will help to boost the response to the first dose. For this reason, until additional information becomes available, further doses are not required. |
| **Duration of treatment** | See Dose and frequency of administration above.  Booster doses of COVID-19 vaccine are not yet recommended because the need for, and timing of, boosters has not yet been determined. |
| **Maximum or minimum treatment period** | See Frequency of administration above. |
| **Quantity to supply/administer** | Administer 0.5mL per administration. |
| **▼ black triangle medicines** | AstraZeneca COVID-19 Vaccine (ChAdOx1-S [Recombinant]) did not have a UK marketing authorisation at the time this PGD was written and is authorised for temporary supply in the UK in accordance with a Regulation 174 authorisation.  All adverse reactions occurring in individuals of any age after vaccination should be reported to the Medicines & Healthcare products Regulatory Agency (MHRA) using the Coronavirus Yellow Card Scheme. Anyone can report a suspected adverse reaction to the MHRA using the Coronavirus Yellow Card reporting scheme <https://coronavirus-yellowcard.mhra.gov.uk/> |
| **Legal category** | AstraZeneca COVID-19 Vaccine (ChAdOx1-S [Recombinant]) is provided temporary authorisation by the MHRA for supply in the UK under regulation 174 and 174A, pending UK marketing authorisation.  The regulation 174 authorised product is categorised as a prescription only medicine (POM). |
| **Is the use out with the SPC?** | AstraZeneca COVID-19 Vaccine (ChAdOx1-S [Recombinant]) is supplied in the UK in accordance with regulation 174 and did not have a UK marketing authorisation at the time of writing this PGD.  As part of the consent process, inform the individual/carer that this vaccine does not have a UK marketing authorisation but has been authorised for temporary supply in the UK by the MHRA and that it is being offered in accordance with national guidance. |
| **Storage requirements** | AstraZeneca COVID-19 Vaccine (ChAdOx1-S [Recombinant]) must be stored in a fridge between +2 to +8°C in accordance with manufacturer’s advice.  During storage it is recommended that the vials are stored in the original packaging/cartons, away from direct sunlight to protect from light and kept upright.  NHS Board guidance on Storage and Handling of vaccines should be observed.  In the event of an inadvertent or unavoidable deviation of these conditions, vaccine that has been stored outside the conditions stated above should be quarantined and risk assessed for suitability of continued use or appropriate disposal.  After first use – use as soon as practically possible and within six hours. The vaccine may be stored between +2 and +25°C during the in-use period in accordance with manufacturer’s advice. The vaccine vial has space to write the date and time that the vial was first punctured; write this on the vial label.  The manufacturer may advise of updated storage requirements and product stability as new data becomes available, vaccine may be stored in accordance with updated recommendations from the manufacturer. |
| **Additional information** | Minor illnesses without fever or systemic upset are not valid reasons to postpone immunisation. If an individual is acutely unwell, immunisation should be postponed until they have fully recovered.  There is no evidence of any safety concerns from vaccinating individuals with a past history of COVID-19 infection, or with detectable COVID-19 antibody.  Vaccination of individuals who may be infected but asymptomatic or incubating COVID-19 infection is unlikely to have a detrimental effect on the illness. Vaccination should be deferred in those with confirmed infection to avoid confusing the differential diagnosis. As clinical deterioration can occur up to two weeks after infection, ideally vaccination should be deferred until around four weeks after onset of symptoms or from the first PCR positive specimen in those who are asymptomatic.  Having prolonged COVID-19 symptoms is not a contraindication to receiving COVID-19 vaccine but if the patient is seriously debilitated, still under active investigation, or has evidence of recent deterioration, deferral of vaccination may be considered to avoid incorrect attribution of any change in the person’s underlying condition to the vaccine. |

# 

# Adverse reactions

|  |  |
| --- | --- |
| Category | Description |
| **Warnings including possible adverse reactions and management of these** | From early phase trials, mild pain and tenderness at the injection site was common with COVID-19 Vaccine (ChAdOx1-S [recombinant]) AstraZeneca occurring in 88% of 18-55 year olds, 73% of 56-69 year olds and 61% of people aged 70 years or over; similar levels were reported after each dose. Short lived systemic symptoms including fatigue and headache were also common but decreased with age, being reported in 86%, 77%, and 65% of those aged 18-55, 56-69 and 70 years or over respectively; most of these were classified as mild or moderate. These reactions were unusual after the second dose. Mild fever (>38˚C) was recorded in the first 48 hours for around a quarter of younger participants but was not reported in those over 55 years of age or in any age group after the second dose. Fever can be modified by the prophylactic use of paracetamol, which does not affect the immune response to this vaccine.  A protocol for the management of anaphylaxis and an anaphylaxis pack must always be available whenever AstraZeneca COVID-19 Vaccine (ChAdOx1-S [Recombinant]) is given. Immediate treatment should include early treatment with 0.5mg intramuscular adrenaline (0.5ml of 1:1000 or 1mg/ml adrenaline), with an early call for help and further IM adrenaline every 5 minutes. The health professionals overseeing the immunisation service must be trained to recognise an anaphylactic reaction and be familiar with techniques for resuscitation of a patient with anaphylaxis.  In the event of a severe adverse reaction individual should be advised to seek medical advice.  For full details/information on possible adverse reaction, refer to manufacturer’s product literature or summary of product characteristics. |
| **Reporting procedure for adverse reactions** | Healthcare professionals and individuals/carers should report suspected adverse reactions to the MHRA using the Coronavirus Yellow Card reporting scheme on: <https://coronavirus-yellowcard.mhra.gov.uk/>  As this vaccine is labelled with a black triangle, all adverse reactions occurring in individuals of any age after vaccination should be reported to the MHRA using the Coronavirus Yellow Card Scheme. Anyone can report a suspected adverse reaction to the MHRA using the Coronavirus Yellow Card reporting scheme <https://coronavirus-yellowcard.mhra.gov.uk/>  Any adverse reaction to a vaccine should be documented in accordance with locally agreed procedures in the individual’s record and the individual’s GP should be informed.  Anaphylaxis is a very rare, recognised side effect of most vaccines and suspected cases should be reported via the Coronavirus Yellow Card Scheme. Chapter 8 of the Green Book gives detailed guidance on distinguishing between faints, panic attacks and the signs and symptoms of anaphylaxis. If a case of suspected anaphylaxis meets the clinical features described in Chapter 8, this should be reported via the Yellow Card Scheme as a case of ‘anaphylaxis’ (or if appropriate ‘anaphylactoid reaction’). Cases of less severe allergic reactions (i.e. not including the clinical features of anaphylaxis) should not be reported as anaphylaxis but as ‘allergic reaction’.  Programmatic Adverse Events should be recorded in line with local procedures and where appropriate escalated in accordance with the national framework. |
| **Advice to patient or carer including written information** | Written information to be given to individual   * Provide manufacturer’s consumer information leaflet/patient information leaflet (PIL) provided with the vaccine. * Provide copy of Public Health Scotland post- vaccination leaflet * Provide copy of Pregnant, planning a pregnancy or breastfeeding, a guide to COVID-19 vaccine to women of child bearing years   Individual advice / follow up treatment   * Inform the individual/carer of possible side effects and their management. * Vaccinated individuals should be advised that it is common to develop a fever after vaccination and that this normally happens within 48 hours after the vaccination and usually goes away within 48 hours. This is a common, expected reaction, and self-isolation and testing for COVID-19 are not required unless the individual has other COVID-19 symptoms; has been told by NHS Test and Protect they are a close contact of someone who has tested positive for COVID-19; they live with someone who has recently tested positive for COVID-19; or they live with someone who has symptoms of COVID-19. * Vaccinated individuals should be advised that if the fever started 48 hours after the vaccination or lasts longer than 48 hours, they should self-isolate and book a test. * Vaccinated individuals should be advised that feeling generally unwell, shivery, achy and tired were also symptoms commonly reported by vaccine recipients in the clinical trials. Generally, these symptoms were found to resolve within one to two days without treatment but paracetamol can be taken if necessary to relieve any of these symptoms. * As has always been recommended, any fever after vaccination should be monitored and if individuals are concerned about their health at any time, they should seek advice from their GP or NHS24 * The individual should be advised to seek medical advice in the event of a severe adverse reaction. * Inform the individual that they can report suspected adverse reactions to the MHRA using the Yellow Card reporting scheme on: <http://yellowcard.mhra.gov.uk> * Immunosuppressed individuals should be advised that they may not make a full immune response to the vaccine and they should continue to take appropriate measures to protect themselves against this infection. * When administration is postponed advise the individual how future vaccination may be accessed * When applicable, advise the individual/carer when to return for vaccination or when a subsequent vaccine dose is due. |
| **Observation following vaccination** | As syncope (fainting) can occur following vaccination, all vaccines should either be driven by someone else or should not drive for 15 minutes after vaccination. |
| **Follow up** | Not applicable |
| **Additional facilities** | A protocol for the management of anaphylaxis and an anaphylaxis pack must always be available whenever AstraZeneca COVID-19 Vaccine (ChAdOx1-S [Recombinant]) is given. Immediate treatment should include early treatment with 0.5mg intramuscular adrenaline (0.5ml of 1:1000 or 1mg/ml adrenaline), with an early call for help and further IM adrenaline every 5 minutes. The health professionals overseeing the immunisation service must be trained to recognise an anaphylactic reaction and be familiar with techniques for resuscitation of a patient with anaphylaxis. |

# Characteristics of staff authorised under the PGD

|  |  |
| --- | --- |
| Category | Description |
| **Professional qualifications** | The following classes of registered healthcare practitioners are permitted to administer AstraZeneca COVID-19 Vaccine (ChAdOx1-S [Recombinant])   * nurses and midwives currently registered with the Nursing and Midwifery Council (NMC) * pharmacists currently registered with the General Pharmaceutical Council (GPhC) * chiropodists/podiatrists, dieticians, occupational therapists, orthoptists, orthotists/prosthetists, paramedics, physiotherapists, radiographers and speech and language therapists currently registered with the Health and Care Professions Council (HCPC) * dental hygienists and dental therapists registered with the General Dental Council * optometrists registered with the General Optical Council. |
| **Specialist competencies or qualifications** | Persons must only work under this PGD where they are competent to do so.  All practitioners operating this PGD must:  a. demonstrate appropriate knowledge and skills to work under the PGD for the administration of COVID-19 vaccine.  b. Have met the requirements of the NES Proficiency document -COVID-19 vaccine administration for registered staff or the NES Proficiency document –COVID-19 vaccine administration. This NES Proficiency document can be found at TURAS Learn at: <https://learn.nes.nhs.scot/37676/immunisation/covid-19-vaccines>  All persons operating this PGD:   * must be authorised by name by their employer as an approved person under the current terms of this PGD before working to it * must be familiar with the vaccine product and alert to changes in the manufacturers product information/summary of product information, * must be competent to undertake immunisation and to discuss issues related to immunisation to assess patients for vaccination and obtain consent * must be competent in the correct storage of vaccines and management of the cold chain if receiving, responsible for, or handling the vaccine * must be competent in the recognition and management of anaphylaxis or under the supervision of persons able to respond appropriately to immediate adverse reactions * must have access to the PGD and associated online resources * should fulfil any additional requirements defined by local policy   All practitioners operating under the PGD are responsible for ensuring they remain up to date with the use of COVID-19 vaccines included. If any training needs are identified these should be discussed with the individuals in the organisation responsible for authorising individuals to act under the PGD  Employer  The employer is responsible for ensuring that persons have the required knowledge and skills to safely deliver the activity they are employed to provide under this PGD  As a minimum, competence requirements stipulated in the PGD must be adhered to. |
| **Continuing education and training** | All practitioners operating under the PGD are responsible for ensuring they remain up to date with the use of COVID-19 vaccines included. If any training needs are identified these should be discussed with the individuals in the organisation responsible for authorising individuals to act under this PGD. |

# 

# Audit trail

|  |  |
| --- | --- |
| Name | Description |
| **Record/ audit trail** | Record:   * that valid informed consent was given * name of individual, address, date of birth and GP with whom the individual is registered * name of person that undertook assessment of individual’s clinical suitability for vaccine * name of person that administered the vaccine * name and brand of vaccine * date of administration * dose, form and route of administration of vaccine * batch number * where possible expiry date * anatomical site of vaccination * advice given, including advice given if excluded or declines immunisation * details of any adverse drug reactions and actions taken * administered under PGD   Records should kept line with local procedures. Ideally records should be kept within the NHS Scotland COVID-19 vaccine administration app.  Local policy should be followed to encourage information sharing with the individual’s General Practice.  All records should be clear, legible and contemporaneous. |

# Additional references

|  |  |
| --- | --- |
| Name | Description |
| **Additional references** | Immunisation against Infectious Disease [Green Book] <https://www.gov.uk/government/organisations/public-health-england/series/immunisation-against-infectious-disease-the-green-book>  Immunisation against Infectious Disease [Green Book] COVID-19 <https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a>  JCVI: advice on priority groups for COVID-19 vaccine 30 December 2020  <https://www.gov.uk/government/publications/priority-groups-for-coronavirus-covid-19-vaccination-advice-from-the-jcvi-30-december-2020>  Manufacturer’s product information/ Summary of Product Characteristics  <https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca>  Educational resources for registered professionals produced by National Education for Scotland  <https://learn.nes.nhs.scot/37676/immunisation/covid-19-vaccines>  All relevant Scottish Government advice including the relevant CMO letter(s) |

# PGD for administration of AstraZeneca COVID-19 Vaccine (ChAdOx1-S [Recombinant]) PGD v1.0 Valid from: 31/12/2020 Expiry: 30/11/2021 - authorisation

### Practitioner

This PGD does not remove professional obligations and accountability. It is the responsibility of each professional to practice within the bounds of their own competence and in accordance with their Code of Professional Conduct and to ensure familiarity with the marketing authorisation holder’s summary of product characteristics for all vaccines administered in accordance with this PGD.

By signing this PGD you are indicating that you agree to its contents and that you will work within it. I agree to administer AstraZeneca COVID-19 Vaccine (ChAdOx1-S [Recombinant]) only in accordance with this PGD.

|  |  |  |
| --- | --- | --- |
| Name of professional | Signature | Date |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |

### Authorising Manager

I confirm that the practitioners named above have declared themselves suitably trained and competent to work under this PGD. I give authorisation on behalf of **[insert name of organisation]** for the above named health care professionals who have signed the PGD to work under it.

Lead clinician for the service area

**Name** ……………………………………………………..

**Signature** ………………………………………………..

**Date** ………………………………………………………

Authorised staff should be provided with an individual copy of the clinical content of the PGD and a photocopy of the document showing their authorisation. This authorisation sheet should be retained to serve as a record of those practitioners authorised to work under this PGD.